GeneThera Valuation
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of GeneThera from evaluating the firm fundamentals such as Current Valuation of 1.44 M, price to earning of (0.17) X, and Return On Asset of -95.38 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that GeneThera's price fluctuation is very steady at this time. Calculation of the real value of GeneThera is based on 3 months time horizon. Increasing GeneThera's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GeneThera pink sheet is determined by what a typical buyer is willing to pay for full or partial control of GeneThera. Since GeneThera is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GeneThera Pink Sheet. However, GeneThera's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The intrinsic value of GeneThera's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GeneThera's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GeneThera helps investors to forecast how GeneThera pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GeneThera more accurately as focusing exclusively on GeneThera's fundamentals will not take into account other important factors: GeneThera Total Value Analysis
GeneThera is currently forecasted to have valuation of 1.44 M with market capitalization of 533.53 K, debt of 806.87 K, and cash on hands of 140.1 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the GeneThera fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.44 M | 533.53 K | 806.87 K | 140.1 K |
GeneThera Asset Utilization
One of the ways to look at asset utilization of GeneThera is to check how much profit was generated for every dollar of assets it reports. GeneThera retains a negative application of resources of -95.38 (percent), losing $0.95 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of GeneThera shows how discouraging it operates for each dollar spent on its resources.GeneThera Ownership Allocation
GeneThera has a total of 35.33 Million outstanding shares. GeneThera retains 17.99 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GeneThera Profitability Analysis
Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0.About GeneThera Valuation
The pink sheet valuation mechanism determines GeneThera's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of GeneThera based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of GeneThera. We calculate exposure to GeneThera's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GeneThera's related companies.GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
8 Steps to conduct GeneThera's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GeneThera's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GeneThera's valuation analysis, follow these 8 steps:- Gather financial information: Obtain GeneThera's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GeneThera's revenue streams: Identify GeneThera's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GeneThera's industry and market trends, including the size of the market, growth rate, and competition.
- Establish GeneThera's growth potential: Evaluate GeneThera's management, business model, and growth potential.
- Determine GeneThera's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GeneThera's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
GeneThera Growth Indicators
Investing in growth stocks can be very risky. If the company such as GeneThera does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 25.4 M | |
| Retained Earnings | -32.3 M |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.